IRS1 and Alzheimer disease: This study demonstrated that significant differences in the IRS1 levels were recognizable up to 10 years prior to clinical onset of AD, which suggests that proteins within BDEs that are involved in insulin disruption may potentially be useful biomarkers for clinical diagnosis.